Xencor, Inc.
XNCR$1.16B
Small CapNASDAQPharmaceutical Preparations🇺🇸North AmericaPASADENA250 employees
Drugs in Pipeline
4
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
XNCR News
Catalyst Timeline
0 upcoming, 0 past
No catalysts found.
Drug Pipeline
XmAb5871
Systemic Lupus Erythematosus
vudalimab monotherapy
Metastatic Castration-Resistant Prostate Cancer
vudalimab
Ovarian Cancer
XmAb942
Ulcerative Colitis (UC)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
XmAb5871 | Phase 2 | Systemic Lupus Erythematosus | - | - |
vudalimab monotherapy | Phase 2 | Metastatic Castration-Resistant Prostate Cancer | - | - |
vudalimab | Phase 2 | Ovarian Cancer | - | - |
XmAb942 | Phase 2 | Ulcerative Colitis (UC) | - | - |
Systemic Lupus Erythematosus
1 drug in this indication
Ovarian Cancer
1 drug in this indication
Metastatic Castration-Resistant Prostate Cancer
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply